Has A J Vinaya Simha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,879 in general payments to A J Vinaya Simha, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean A J Vinaya Simha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about A J Vinaya Simha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

A J Vinaya Simha, MD

Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1740259241

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Aegerion Pharmaceuticals, Inc. at 54.9% of the total. Reporting peaked in 2019 at $2,689 and has fallen 99.1% since, to $24 in 2025.

$4,879in general payments, 2019–2025

Across 11 payments — averaging $443.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aegerion Pharmaceuticals, Inc.$3K
Pfizer$2K
Salvin Dental Specialties, Inc.$328
Regeneron Healthcare Solutions, Inc.$50
Abbott$24

$133,769in research payments, 2019–2025

Across 64 payments — averaging $2090.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amryt Pharma Holdings Ltd$65K
Chiesi USA, Inc.$52K
Akcea Therapeutics, Inc.$17K

What the payments were for

Consulting fees$2,56052%
Speaking & faculty fees$1,80037%
Food & beverage$46810%
Education$501%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aegerion Pharmaceuticals, Inc.	4	$2,677
Pfizer	1	$1,800
Salvin Dental Specialties, Inc.	2	$328
Regeneron Healthcare Solutions, Inc.	3	$50
Abbott	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MYALEPT$2,560

How this compares

$4,879 in reported general payments places this provider in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota →

Medicare billing

Part B allowed, 2024

$50,384

Medicare patients

411

Services billed

643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrulicityDulaglutide	111	$138,213
MounjaroTirzepatide	101	$123,397
OzempicSemaglutide	112	$122,780
JardianceEmpagliflozin	63	$57,078
RybelsusSemaglutide	48	$54,678
Repatha SureclickEvolocumab	54	$36,229
Tresiba Flextouch U-100Insulin Degludec	22	$25,430
Humulin R U-500 KwikpenInsulin Regular, Human	16	$21,489
FarxigaDapagliflozin Propanediol	14	$19,171
Humalog Kwikpen U-100Insulin Lispro	41	$16,307
Praluent PenAlirocumab	14	$15,085
VascepaIcosapent Ethyl	15	$13,352
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	86	$11,979
Novolog FlexpenInsulin Aspart	35	$10,423
Icosapent Ethyl	17	$8,862

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Rochester

Marjorie Ann MalbasRochester$222K
Irina BancosRochester$114K
Maria CastroRochester$63K
Marius StanRochester$59K
Matthew DrakeRochester$41K
Manpreet MundiRochester$39K
Yogish KudvaRochester$38K
Bart ClarkeRochester$36K
Robert RizzaRochester$30K
Adrian VellaRochester$26K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →